» Articles » PMID: 36623926

Antibiotic Use As a Risk Factor for Inflammatory Bowel Disease Across the Ages: a Population-based Cohort Study

Overview
Journal Gut
Specialty Gastroenterology
Date 2023 Jan 9
PMID 36623926
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is an increasing incidence of inflammatory bowel disease (IBD) for which environmental factors are suspected. Antibiotics have been associated with development of IBD in earlier generations, but their influence on IBD risk in adults is uncertain.

Objective: To assess the impact of antibiotic exposure, including dose-response, timing and antibiotic class, on the risk of IBD in all individuals aged ≥10 years.

Design: Using Denmark nationwide registries, a population-based cohort of residents aged ≥10 years was established between 2000 and 2018. Incidence rate ratios (IRRs) for IBD following antibiotic exposure were calculated using Poisson regression.

Results: There were a total of 6 104 245 individuals, resulting in 87 112 328 person-years of follow-up, and 52 898 new cases of IBD. Antibiotic exposure was associated with an increased risk of IBD as compared with no antibiotic exposure for all age groups, although was greatest among individuals aged 40-60 years and ≥60 years (age 10-40 years, IRR 1.28, 95% CI 1.25 to 1.32; age 40-60 years, IRR 1.48, 95% CI 1.43 to 1.54; age ≥60 years, IRR 1.47, 95% CI 1.42 to 1.53). For all age groups a positive dose-response was observed, with similar results seen for both ulcerative colitis and Crohn's disease. The highest risk of developing IBD was seen 1-2 years after antibiotic exposure, and after use of antibiotic classes often prescribed to treat gastrointestinal pathogens.

Conclusion: Antibiotic exposure is associated with an increased risk of IBD, and was highest among individuals aged 40 years and older. This risk increased with cumulative antibiotic exposure, with antibiotics targeting gastrointestinal pathogens and within 1-2 years after antibiotic exposure.

Citing Articles

Early-life antibiotic exposure aggravates hepatic steatosis through enhanced endotoxemia and lipotoxic effects driven by gut .

Zhang X, Chan D, Zhu J, Sin D, Peng Y, Wong M MedComm (2020). 2025; 6(3):e70104.

PMID: 39968496 PMC: 11832435. DOI: 10.1002/mco2.70104.


Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions.

Little R, Jayawardana T, Koentgen S, Zhang F, Connor S, Boussioutas A eGastroenterology. 2025; 2(1):e100006.

PMID: 39944752 PMC: 11770437. DOI: 10.1136/egastro-2023-100006.


Causal role of the gut microbiome in certain human diseases: a narrative review.

Prosty C, Katergi K, Papenburg J, Lawandi A, Lee T, Shi H eGastroenterology. 2025; 2(3):e100086.

PMID: 39944364 PMC: 11770457. DOI: 10.1136/egastro-2024-100086.


Do Antibiotics Cause Inflammatory Bowel Disease? A Systematic Review and Meta-Analysis.

Scharf E, Schlattmann P, Stallhofer J, Stallmach A Visc Med. 2025; 41(1):32-47.

PMID: 39927188 PMC: 11801854. DOI: 10.1159/000541601.


Unlocking the secrets of the human gut microbiota: Comprehensive review on its role in different diseases.

Paul J, Azmal M, Haque A, Meem M, Talukder O, Ghosh A World J Gastroenterol. 2025; 31(5):99913.

PMID: 39926224 PMC: 11718612. DOI: 10.3748/wjg.v31.i5.99913.


References
1.
Stamatiades G, Ioannou P, Petrikkos G, Tsioutis C . Fungal infections in patients with inflammatory bowel disease: A systematic review. Mycoses. 2018; 61(6):366-376. PMC: 5980782. DOI: 10.1111/myc.12753. View

2.
Everhov A, Halfvarson J, Myrelid P, Sachs M, Nordenvall C, Soderling J . Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden. Gastroenterology. 2017; 154(3):518-528.e15. DOI: 10.1053/j.gastro.2017.10.034. View

3.
Ungaro R, Bernstein C, Gearry R, Hviid A, Kolho K, Kronman M . Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol. 2014; 109(11):1728-38. DOI: 10.1038/ajg.2014.246. View

4.
Jackson M, Goodrich J, Maxan M, Freedberg D, Abrams J, Poole A . Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016; 65(5):749-56. PMC: 4853574. DOI: 10.1136/gutjnl-2015-310861. View

5.
Risum M, Astvad K, Krogh Johansen H, Schonheyder H, Rosenvinge F, Knudsen J . Update 2016-2018 of the Nationwide Danish Fungaemia Surveillance Study: Epidemiologic Changes in a 15-Year Perspective. J Fungi (Basel). 2021; 7(6). PMC: 8235436. DOI: 10.3390/jof7060491. View